High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: The Bologna experience

Pier Luigi Zinzani, Monica Tani, Annalisa Gabrielle, Filippo Gherlinzoni, Antonello De Vivo, Paolo Ricci, Giuseppe Bandini, Roberto Massimo Lemoli, Maria Rosa Motta, Simonetta Rizzi, Valeria Guidice, Maurizio Zompatori, Vittorio Stefoni, Lapo Alinari, Gerardo Musuraca, Enrica Marchi, Simona Bassi, Roberto Conte, Stefano Pileri, Sante TuraMichele Baccarani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with aggressive non-Hodgkin's lymphoma (NHL) who relapse after initial therapy have a poor prognosis and with standard dose salvage therapy the outlook remains poor. In this work we examine the patient characteristics and outcome of patients with aggressive NHL treated with HDT and autologous transplantation at our Institute from 1982 to 1999. A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for hematopietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). One hundred and thirty-four patients with aggressive NHL were treated with estimated 10-year OS and RFS rates of 50% and 66%, respectively. Disease status (sensitive vs. refractory) pre-HDT was the most powerful predictive parameter for OS and RFS, at both univariate and multivariate analysis. For the entire cohort, transplant-related mortality was only 3.5% without evidence of second malignancies. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of aggressive NHL patients with very low global early and late toxicity. Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalLeukemia and Lymphoma
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Autologous Transplantation
Non-Hodgkin's Lymphoma
Recurrence
Survival
Therapeutics
Survival Rate
Transplants
Salvage Therapy
Second Primary Neoplasms
Patient Selection
Stem Cells
Multivariate Analysis
Transplantation
Drug Therapy
Mortality

Keywords

  • ABMT
  • Aggressive non-Hodgkin's lymphoma
  • Chemotherapy
  • Relapse-free survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Zinzani, P. L., Tani, M., Gabrielle, A., Gherlinzoni, F., De Vivo, A., Ricci, P., ... Baccarani, M. (2004). High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: The Bologna experience. Leukemia and Lymphoma, 45(2), 321-326. https://doi.org/10.1080/10428190310001597900

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma : The Bologna experience. / Zinzani, Pier Luigi; Tani, Monica; Gabrielle, Annalisa; Gherlinzoni, Filippo; De Vivo, Antonello; Ricci, Paolo; Bandini, Giuseppe; Lemoli, Roberto Massimo; Motta, Maria Rosa; Rizzi, Simonetta; Guidice, Valeria; Zompatori, Maurizio; Stefoni, Vittorio; Alinari, Lapo; Musuraca, Gerardo; Marchi, Enrica; Bassi, Simona; Conte, Roberto; Pileri, Stefano; Tura, Sante; Baccarani, Michele.

In: Leukemia and Lymphoma, Vol. 45, No. 2, 02.2004, p. 321-326.

Research output: Contribution to journalArticle

Zinzani, PL, Tani, M, Gabrielle, A, Gherlinzoni, F, De Vivo, A, Ricci, P, Bandini, G, Lemoli, RM, Motta, MR, Rizzi, S, Guidice, V, Zompatori, M, Stefoni, V, Alinari, L, Musuraca, G, Marchi, E, Bassi, S, Conte, R, Pileri, S, Tura, S & Baccarani, M 2004, 'High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: The Bologna experience', Leukemia and Lymphoma, vol. 45, no. 2, pp. 321-326. https://doi.org/10.1080/10428190310001597900
Zinzani, Pier Luigi ; Tani, Monica ; Gabrielle, Annalisa ; Gherlinzoni, Filippo ; De Vivo, Antonello ; Ricci, Paolo ; Bandini, Giuseppe ; Lemoli, Roberto Massimo ; Motta, Maria Rosa ; Rizzi, Simonetta ; Guidice, Valeria ; Zompatori, Maurizio ; Stefoni, Vittorio ; Alinari, Lapo ; Musuraca, Gerardo ; Marchi, Enrica ; Bassi, Simona ; Conte, Roberto ; Pileri, Stefano ; Tura, Sante ; Baccarani, Michele. / High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma : The Bologna experience. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 2. pp. 321-326.
@article{5cb30509b66f4f7aa5910cfd18c2a532,
title = "High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: The Bologna experience",
abstract = "Patients with aggressive non-Hodgkin's lymphoma (NHL) who relapse after initial therapy have a poor prognosis and with standard dose salvage therapy the outlook remains poor. In this work we examine the patient characteristics and outcome of patients with aggressive NHL treated with HDT and autologous transplantation at our Institute from 1982 to 1999. A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for hematopietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). One hundred and thirty-four patients with aggressive NHL were treated with estimated 10-year OS and RFS rates of 50{\%} and 66{\%}, respectively. Disease status (sensitive vs. refractory) pre-HDT was the most powerful predictive parameter for OS and RFS, at both univariate and multivariate analysis. For the entire cohort, transplant-related mortality was only 3.5{\%} without evidence of second malignancies. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of aggressive NHL patients with very low global early and late toxicity. Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further.",
keywords = "ABMT, Aggressive non-Hodgkin's lymphoma, Chemotherapy, Relapse-free survival",
author = "Zinzani, {Pier Luigi} and Monica Tani and Annalisa Gabrielle and Filippo Gherlinzoni and {De Vivo}, Antonello and Paolo Ricci and Giuseppe Bandini and Lemoli, {Roberto Massimo} and Motta, {Maria Rosa} and Simonetta Rizzi and Valeria Guidice and Maurizio Zompatori and Vittorio Stefoni and Lapo Alinari and Gerardo Musuraca and Enrica Marchi and Simona Bassi and Roberto Conte and Stefano Pileri and Sante Tura and Michele Baccarani",
year = "2004",
month = "2",
doi = "10.1080/10428190310001597900",
language = "English",
volume = "45",
pages = "321--326",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma

T2 - The Bologna experience

AU - Zinzani, Pier Luigi

AU - Tani, Monica

AU - Gabrielle, Annalisa

AU - Gherlinzoni, Filippo

AU - De Vivo, Antonello

AU - Ricci, Paolo

AU - Bandini, Giuseppe

AU - Lemoli, Roberto Massimo

AU - Motta, Maria Rosa

AU - Rizzi, Simonetta

AU - Guidice, Valeria

AU - Zompatori, Maurizio

AU - Stefoni, Vittorio

AU - Alinari, Lapo

AU - Musuraca, Gerardo

AU - Marchi, Enrica

AU - Bassi, Simona

AU - Conte, Roberto

AU - Pileri, Stefano

AU - Tura, Sante

AU - Baccarani, Michele

PY - 2004/2

Y1 - 2004/2

N2 - Patients with aggressive non-Hodgkin's lymphoma (NHL) who relapse after initial therapy have a poor prognosis and with standard dose salvage therapy the outlook remains poor. In this work we examine the patient characteristics and outcome of patients with aggressive NHL treated with HDT and autologous transplantation at our Institute from 1982 to 1999. A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for hematopietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). One hundred and thirty-four patients with aggressive NHL were treated with estimated 10-year OS and RFS rates of 50% and 66%, respectively. Disease status (sensitive vs. refractory) pre-HDT was the most powerful predictive parameter for OS and RFS, at both univariate and multivariate analysis. For the entire cohort, transplant-related mortality was only 3.5% without evidence of second malignancies. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of aggressive NHL patients with very low global early and late toxicity. Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further.

AB - Patients with aggressive non-Hodgkin's lymphoma (NHL) who relapse after initial therapy have a poor prognosis and with standard dose salvage therapy the outlook remains poor. In this work we examine the patient characteristics and outcome of patients with aggressive NHL treated with HDT and autologous transplantation at our Institute from 1982 to 1999. A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for hematopietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). One hundred and thirty-four patients with aggressive NHL were treated with estimated 10-year OS and RFS rates of 50% and 66%, respectively. Disease status (sensitive vs. refractory) pre-HDT was the most powerful predictive parameter for OS and RFS, at both univariate and multivariate analysis. For the entire cohort, transplant-related mortality was only 3.5% without evidence of second malignancies. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of aggressive NHL patients with very low global early and late toxicity. Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further.

KW - ABMT

KW - Aggressive non-Hodgkin's lymphoma

KW - Chemotherapy

KW - Relapse-free survival

UR - http://www.scopus.com/inward/record.url?scp=10744227441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744227441&partnerID=8YFLogxK

U2 - 10.1080/10428190310001597900

DO - 10.1080/10428190310001597900

M3 - Article

C2 - 15101718

AN - SCOPUS:10744227441

VL - 45

SP - 321

EP - 326

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -